The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective

Authors :: Bousquet, J. Jutel, M. Pfaar, O. Fonseca, J.A. Agache, I. Czarlewski, W. Bachert, C. Bergmann, K.C. Cruz, A.A. Klimek, L. Kvedariene, V. Larenas-Linnemann, D.E. Papadopoulos, N.G. Patella, V. Regateiro, F.S. Scichilone, N. Shamji, M.H. Sheikh, A. Valovirta, E. Ventura, M.-T. Zuberbier, T.
Publication Year :: 2021
Abstract: Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many international or national practice guidelines have been produced, but the evidence-based method varies and they do not usually propose care pathways. The present article considers the possible role of mobile health in AIT for allergic rhinitis/asthma. There are no currently available validated biologic biomarkers that can predict AIT success, and mobile health biomarkers have some relevance. In the current article, the following aspects will be discussed: patient stratification for AIT, symptom-medication scores for the follow-up of patients, clinical trials, as well as the approach of the European Academy of Allergy and Clinical Immunology. © 2021 American Academy of Allergy, Asthma & Immunology

Tools